Richard Kyle Lacher graduated with a Bachelor of Science in Behavioral Neuroscience from the University of Cincinnati in 2008. After graduation he began his carrier at Yale University, studying the effects of early life stress on adolescent brain development and characterizing immune cell populations involved in tumor progression. He returned to his hometown of Cincinnati in 2016 in order to study the roles of microRNAs in epilepsy at Cincinnati Children’s Hospital. In 2022 he joined the Neurobehavioral Treatment Discovery Team under Craig Erickson, MD. His current research focuses on investigating novel preclinical drug treatments and electrophysiological biomarker discovery in mouse models of Fragile X Syndrome.